Yayın:
186 Effects of an established drug on smad signalling pathway in the rat model of monocrotaline pulmonary hypertension

Sadeleştirilmiş öğe sayfası
dc.contributor.authorKhaled Habas
dc.contributor.authorÖzlem Atlı Eklioğlu
dc.contributor.authorATLI EKLİOĞLU, ÖZLEM
dc.contributor.authorTalat Nasim
dc.contributor.orcid0009-0003-7854-9300
dc.contributor.orcid0000-0002-6131-3399
dc.contributor.orcid0000-0003-1968-5663
dc.date.accessioned2025-11-13T20:37:17Z
dc.date.issued2021-06-01
dc.identifier.doihttps://doi.org/10.1136/heartjnl-2021-bcs.183
dc.identifier.openalexW3171477060
dc.identifier.urihttps://hdl.handle.net/11421/12417
dc.identifier.urihttps://doi.org/10.1136/heartjnl-2021-bcs.183
dc.language.isoen
dc.rightsopenAccess
dc.subjectSMAD
dc.subjectBMPR2
dc.subjectMedicine
dc.subjectSignal transduction
dc.subjectPhosphorylation
dc.subjectBone morphogenetic protein receptor
dc.subjectPulmonary hypertension
dc.subjectWestern blot
dc.subjectPulmonary artery
dc.subjectBone morphogenetic protein
dc.subjectPharmacology
dc.subjectReceptor
dc.subjectInternal medicine
dc.subjectCancer research
dc.subjectEndocrinology
dc.subjectCell biology
dc.subjectGene
dc.subjectBiology
dc.subjectBiochemistry
dc.subject.sdg3
dc.title186 Effects of an established drug on smad signalling pathway in the rat model of monocrotaline pulmonary hypertension
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5087171830

Dosyalar

Koleksiyonlar

Publications